List view / Grid view
Victoria Rees (European Pharmaceutical Review)
Filter the results
The two pharmaceutical companies are facing a legal battle after Mylan filed a new drug application for a generic of Novo Nordisk’s Victoza.
A study has found that between 2014 and 2016, the EMA and FDA had very little divergence in their marketing authorisation decisions.
New research has found that of the 38 warning letters handed out by the FDA in 2019, the US and India received the vast majority.
A new biosimilar drug to treat osteoporosis is now available across Europe after the patent for its reference product expired.
Brüün has announced he will be leaving his role as CEO at the BPS and moving to a new role at the Royal College of Anaesthetists.
This series investigates cannabinoids and pharmaceutical interest with industry experts explaining the position of the ingredient. In this second piece, we discuss the challenges, legal implications and perceptions of cannabinoids.
The FDA has accepted an IND application for AG017, a new drug designed to treat the causes of coeliac disease which will soon enter new trials.
The pharmaceutical company has received a complete response letter for its golodirsen injection, which had been submitted for accelerated approval.
The FDA has given its approval to RINVOQ for the treatment of active rheumatoid arthritis after the drug reached its endpoints in clinical trials.
The worldwide trade of the cephalosporin class of antibiotics will increase to $14.1 billion by the end of 2025.
A leaked government dossier has stated that in the event of a no-deal Brexit, the UK will face severe medicinal shortages.
Researchers have developed silica spheres to contain cancer therapeutics that melt at certain temperatures and have the potential to improve drug delivery.